Ruxolitinib
Sign in to save this workspacePrimary targets: JAK1, JAK2, JAK3, TYK2 · FDA status: FDA Approved
Selectivity scorecard
KISS
98.25
Gini
0.592
CATDS
0.018
Computed from wild-type kinome inhibition at 1 μM. Gini reproduces the published values within tolerance; KISS and CATDS are computed but pending reconciliation with the paper's reference code.
Polypharmacology radar
Top 20 strongest-inhibited wild-type kinases for Ruxolitinib. Strongest target: JAK2 at 100.0% inhibition.
Accessible data table
| Rank | Target | Inhibition % | Residual activity % |
|---|---|---|---|
| 1 | JAK2 | 100.0% | 0.0% |
| 2 | JAK3 | 99.2% | 0.8% |
| 3 | TYK2 | 99.0% | 1.0% |
| 4 | JAK1 | 96.7% | 3.3% |
| 5 | CAMK2A | 93.0% | 7.0% |
| 6 | CAMK2D | 90.5% | 9.5% |
| 7 | STK38L_NDR2 | 90.0% | 10.0% |
| 8 | DMPK2 | 87.1% | 12.9% |
| 9 | STK38_NDR1 | 86.6% | 13.4% |
| 10 | ACK1 | 78.5% | 21.5% |
| 11 | TRKC | 75.2% | 24.8% |
| 12 | LATS1 | 71.2% | 28.8% |
| 13 | CDK8_CYCLIN_C | 69.0% | 31.0% |
| 14 | CDK19_CYCLIN_C | 66.6% | 33.4% |
| 15 | ROCK1 | 63.6% | 36.4% |
| 16 | LRRK2 | 63.0% | 37.0% |
| 17 | MEKK3 | 57.0% | 43.0% |
| 18 | LIMK1 | 54.3% | 45.7% |
| 19 | MEKK2 | 52.6% | 47.4% |
| 20 | ALK | 52.1% | 47.9% |
Selectivity landscape
Where Ruxolitinib sits in the 92-drug selectivity landscape (KISS vs Gini). The highlighted point is Ruxolitinib.
Annotations
Sign in to read and post annotations.
Loading…